SCHEMBL1574544

SCHEMBL1574544

CCCN(c1ccccc1)C1CN(C(=O)Nc2ccc(C(C)C)cc2)C1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.48
KMT2A Q03164 2/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
MAPT P10636 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
UBE2M P61081 1/20 0.46
DCUN1D1 Q96GG9 1/20 0.46
NAMPT P43490 3/20 0.45
PANK3 Q9H999 3/20 0.44
CRHBP P24387 1/20 0.44
CRHR2 Q13324 1/20 0.44
TRPV1 Q8NER1 2/20 0.43
CNR2 P34972 1/20 0.42
ELOVL6 Q9H5J4 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1575197 0.91 FAAH (0.50) FAAHKMT2ANPC1RAB9AMAPT
SCHEMBL1575336 0.90 HPGD (0.47) FAAHNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL1574960 0.89 MAPT (0.49) FAAHKMT2ANPC1RAB9AMAPT
SCHEMBL1574520 0.88 GRIN2B (0.51) FAAHNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL1574710 0.87 GRIN2B (0.52) FAAHKMT2ANPC1RAB9AMAPT
SCHEMBL1575479 0.85 GRIN2B (0.55) FAAHKMT2ANPC1RAB9AMAPT
SCHEMBL1574541 0.85 UBE2M (0.45) FAAHKMT2ANPC1RAB9AMAPT
SCHEMBL1574659 0.84 NPC1 (0.52) FAAHKMT2ANPC1RAB9AMAPT
SCHEMBL1575261 0.84 KMT2A (0.57) FAAHKMT2ANPC1RAB9AMAPT
SCHEMBL1575217 0.83 NPSR1 (0.46) KMT2ANPC1RAB9AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-B1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO (JP) 2015-02-25 EP disclosed
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB FAAH 3484/4885KMT2A 2539/4885NPC1 413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.